SKIN CANCERS

>

Latest News

Atlas Examines Tolerability of Hedgehog Pathway Inhibitors and Transition to IO in mBCC
Atlas Examines Tolerability of Hedgehog Pathway Inhibitors and Transition to IO in mBCC

October 16th 2024

During a Case-Based Roundtable® event, Jennifer L. Atlas, MD, discussed treatment for a patient with basal cell carcinoma who reported challenging adverse events with hedgehog pathway inhibitor.

Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma
Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma

October 11th 2024

Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival
Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival

September 23rd 2024

Tawbi Discusses the Role of Brain Metastases and PD-L1 Status in Melanoma
Tawbi Discusses the Role of Brain Metastases and PD-L1 Status in Melanoma

September 11th 2024

VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma
VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma

September 9th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

More News

Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response

Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response

August 17th 2016

Watch

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

August 17th 2016

Watch

Jason Luke, MD: Predicting Which Patients Will Experience Durable Responses to Targeted Therapy

Jason Luke, MD: Predicting Which Patients Will Experience Durable Responses to Targeted Therapy

August 17th 2016

Watch

Jason Luke, MD: The Role of LDH, Age, and Sites of Disease in Durability of Response

Jason Luke, MD: The Role of LDH, Age, and Sites of Disease in Durability of Response

August 17th 2016

Watch

Jason Luke, MD: The Association Between Durable Response and Low Disease Burden

Jason Luke, MD: The Association Between Durable Response and Low Disease Burden

August 17th 2016

Watch

Jason Luke, MD: Factors to Consider When Determining Treatments

Jason Luke, MD: Factors to Consider When Determining Treatments

August 17th 2016

Watch

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1

August 16th 2016

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Watch

Jason Luke, MD: Second-Line Therapy

Jason Luke, MD: Second-Line Therapy

August 16th 2016

Watch

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Second-Line Therapy

Jeffrey Weber, MD, PhD: Second-Line Therapy

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

August 16th 2016

Watch

Jason Luke, MD: Durability of a Response to Targeted Therapy Combination

Jason Luke, MD: Durability of a Response to Targeted Therapy Combination

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination

Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination

August 16th 2016

Watch

Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment

August 16th 2016

Watch

Jason Luke, MD: Factors to Consider When Determining Treatment

Jason Luke, MD: Factors to Consider When Determining Treatment

August 16th 2016

Watch

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD

August 4th 2016

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD

Watch

Adil Daud, MD: Sequencing Challenges in Melanoma

Adil Daud, MD: Sequencing Challenges in Melanoma

August 4th 2016

Watch

Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma

Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma

August 4th 2016

Watch

Adil Daud, MD: Treatment Options in Melanoma

Adil Daud, MD: Treatment Options in Melanoma

August 4th 2016

Watch

Adil Daud, MD: Ordering BRAF Reflexively Upon Diagnosis in Melanoma

Adil Daud, MD: Ordering BRAF Reflexively Upon Diagnosis in Melanoma

August 4th 2016

Watch

Boris C. Bastian, MD, PhD: Upfront BRAF Testing in Melanoma

Boris C. Bastian, MD, PhD: Upfront BRAF Testing in Melanoma

August 4th 2016

Watch

Adil Daud, MD: Frequency of Missed BRAF Alterations in Melanoma

Adil Daud, MD: Frequency of Missed BRAF Alterations in Melanoma

August 4th 2016

Watch

Boris C. Bastian, MD, PhD: BioMerieux and Other Tests in Melanoma

Boris C. Bastian, MD, PhD: BioMerieux and Other Tests in Melanoma

August 4th 2016

Watch

Boris C. Bastian, MD, PhD: Mutations To Test For in Melanoma

Boris C. Bastian, MD, PhD: Mutations To Test For in Melanoma

August 4th 2016

Watch

Boris C. Bastian, MD, PhD: What to do With a Negative Test Result in Melanoma

Boris C. Bastian, MD, PhD: What to do With a Negative Test Result in Melanoma

August 4th 2016

Watch

Boris C. Bastian, MD, PhD: Frequency of Missed BRAF Alterations in Melanoma

Boris C. Bastian, MD, PhD: Frequency of Missed BRAF Alterations in Melanoma

August 4th 2016

Watch

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

July 16th 2016

With 2 different BRAF/MEK combination regimens approved by the FDA, as well as an immunotherapy combination, treatment and sequencing decisions for metastatic BRAF-mutated melanoma can be difficult.

Read More

From the Chairman: Moving Forward With Bold Innovation

From the Chairman: Moving Forward With Bold Innovation

Mike Hennessy, Sr, Chairman
July 14th 2016

As I write this, the 2016 ASCO conference has just concluded in Chicago. And, as is typical with this event, the amount and level of groundbreaking research and information presented at this year's conference is nothing less than staggering in its scope, innovation, and promise.

Read More

<1
...
171819202122232425
...
33>